Study of Raltitrexed and Gemcitabine for Pancreatic Cancer
Author Information
Author(s): Arends J J, Sleeboom H P, Leys M B L, ten Bokkel Huinink D, de Jong R S, Smit J M, Nortier J W R, Tesselaar M E T
Primary Institution: Leiden University Medical Center
Hypothesis
The study aimed to assess the efficacy and tolerability of a combination of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
Conclusion
The combination of raltitrexed and gemcitabine cannot be recommended for patients with advanced pancreatic cancer due to limited efficacy and significant toxicity.
Supporting Evidence
- Four patients experienced grade 4 diarrhoea.
- One patient with grade 4 neutropenia died due to sepsis.
- Only one patient showed a partial response to the treatment.
Takeaway
Doctors tested a new medicine combination for patients with a serious type of pancreatic cancer, but it didn't work well enough to help them.
Methodology
Patients received raltitrexed and gemcitabine in a 21-day treatment cycle, and their responses and side effects were monitored.
Limitations
The study had a small sample size and a high rate of toxicity, which limited the ability to assess efficacy.
Participant Demographics
The median age of participants was 59 years, with a mix of male and female patients and varying performance statuses.
Statistical Information
Confidence Interval
95% CI -3–11%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website